Humana (HUM) Stock Forecast, Price Target & Predictions
HUM Stock Forecast
Humana stock forecast is as follows: an average price target of $500.84 (represents a 55.75% upside from HUM’s last price of $321.56) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.
HUM Price Target
The average price target for Humana (HUM) is $500.84 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $652.00 to $360.00. This represents a potential 55.75% upside from HUM's last price of $321.56.
HUM Analyst Ratings
According to 21 Wall Street analysts, Humana's rating consensus is 'Hold'. The analyst rating breakdown for HUM stock is 0 'Strong Buy' (0.00%), 10 'Buy' (47.62%), 11 'Hold' (52.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Humana Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Frank Morgan | RBC Capital | $400.00 | $364.06 | 9.87% | 24.39% |
| Aug 01, 2024 | Michael Wiederhorn | Oppenheimer | $400.00 | $361.61 | 10.62% | 24.39% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $400.00 | $382.22 | 4.65% | 24.39% |
| Jun 25, 2024 | Jessica Tassan | Piper Sandler | $392.00 | $355.80 | 10.17% | 21.91% |
| Jun 20, 2024 | Andrew Mok | Barclays | $370.00 | $349.55 | 5.85% | 15.06% |
| Apr 25, 2024 | Michael Wiederhorn | Oppenheimer | $370.00 | $315.98 | 17.10% | 15.06% |
| Apr 25, 2024 | Frank Morgan | RBC Capital | $353.00 | $315.98 | 11.72% | 9.78% |
| Apr 25, 2024 | Sarah James | Cantor Fitzgerald | $360.00 | $315.98 | 13.93% | 11.95% |
| Apr 02, 2024 | Andrew Mok | Barclays | $310.00 | $351.45 | -11.79% | -3.59% |
| Feb 07, 2023 | - | Truist Financial | $560.00 | $474.10 | 18.12% | 74.15% |
The latest Humana stock forecast, released on Sep 05, 2024 by Frank Morgan from RBC Capital, set a price target of $400.00, which represents a 9.87% increase from the stock price at the time of the forecast ($364.06), and a 24.39% increase from HUM last price ($321.56).
Humana Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 5 | 9 |
| Avg Price Target | $400.00 | $392.40 | $372.78 |
| Last Closing Price | $321.56 | $321.56 | $321.56 |
| Upside/Downside | 24.39% | 22.03% | 15.93% |
In the current month, the average price target of Humana stock is $400.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 24.39% increase as opposed to Humana's last price of $321.56. This month's average price target is up 1.94% compared to last quarter, and up 7.30% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Raymond James | Underperform | Underperform | Hold |
| Sep 05, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 05, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 19, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Aug 01, 2024 | Raymond James | Buy | Buy | Hold |
| Aug 01, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 15, 2024 | UBS | Buy | Buy | Hold |
| Jun 24, 2024 | Morgan Stanley | Overweight | Equal-Weight | Initialise |
| Jun 20, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jun 12, 2024 | Wells Fargo | Buy | Buy | Hold |
Humana's last stock rating was published by Raymond James on Sep 05, 2024. The company gave HUM a "Underperform" rating, the same as its previous rate.
Humana Financial Forecast
Humana Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $26.42B | $26.75B | $26.74B | $22.44B | $22.80B | - | $23.97B | $21.05B | $20.70B | $20.64B | $20.67B | $19.06B | $20.07B | $19.08B | $18.93B | $16.30B | $16.24B |
| Avg Forecast | $30.79B | $30.74B | $31.71B | $31.96B | $28.98B | $29.05B | $29.97B | $30.40B | $28.66B | $28.67B | $28.52B | $28.52B | $25.51B | $25.57B | $25.83B | $26.43B | $22.48B | $22.82B | $23.45B | $23.54B | $21.22B | $20.90B | $20.51B | $20.48B | $18.77B | $18.62B | $18.64B | $18.45B | $16.19B | $16.15B |
| High Forecast | $31.31B | $31.27B | $32.26B | $32.50B | $29.48B | $29.55B | $30.48B | $30.92B | $29.15B | $28.92B | $29.01B | $29.01B | $25.86B | $26.79B | $26.27B | $26.88B | $22.86B | $23.20B | $23.45B | $24.24B | $21.86B | $21.53B | $21.12B | $21.09B | $19.33B | $19.18B | $19.20B | $19.01B | $16.68B | $16.64B |
| Low Forecast | $30.35B | $30.31B | $31.26B | $31.50B | $28.57B | $28.64B | $29.54B | $29.97B | $28.25B | $28.32B | $28.12B | $28.12B | $25.32B | $24.74B | $25.46B | $26.05B | $22.16B | $22.49B | $23.45B | $22.97B | $20.70B | $20.40B | $20.01B | $19.98B | $18.31B | $18.17B | $18.19B | $18.00B | $15.80B | $15.76B |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 5 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.04% | 1.01% | 1.00% | 1.00% | - | 1.02% | 0.99% | 0.99% | 1.01% | 1.01% | 1.02% | 1.08% | 1.02% | 1.03% | 1.01% | 1.01% |
Humana's average Quarter revenue forecast for Dec 23 based on 5 analysts is $25.51B, with a low forecast of $25.32B, and a high forecast of $25.86B. HUM's average Quarter revenue forecast represents a -3.44% decrease compared to the company's last Quarter revenue of $26.42B (Sep 23).
Humana EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 5 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.40B | $1.57B | $1.90B | $252.00M | $1.62B | - | $1.51B | $220.00M | $1.92B | $1.02B | $1.30B | $-220.00M | $2.03B | $2.84B | $930.00M | $789.00M | $1.11B |
| Avg Forecast | $1.76B | $1.76B | $1.82B | $1.83B | $1.66B | $1.66B | $1.72B | $1.74B | $1.64B | $1.64B | $1.63B | $1.71B | $1.46B | $1.47B | $1.48B | $1.56B | $1.29B | $2.01B | $1.29B | $1.23B | $202.78M | $1.83B | $1.02B | $1.18B | $-226.50M | $1.83B | $2.20B | $786.92M | $760.31M | $1.00B |
| High Forecast | $1.79B | $1.79B | $1.85B | $1.86B | $1.69B | $1.69B | $1.75B | $1.77B | $1.67B | $1.66B | $1.66B | $2.05B | $1.48B | $1.53B | $1.50B | $1.87B | $1.31B | $2.41B | $1.29B | $1.48B | $243.34M | $2.19B | $1.22B | $1.42B | $-181.20M | $2.20B | $2.65B | $944.31M | $912.37M | $1.20B |
| Low Forecast | $1.74B | $1.74B | $1.79B | $1.80B | $1.64B | $1.64B | $1.69B | $1.72B | $1.62B | $1.62B | $1.61B | $1.37B | $1.45B | $1.42B | $1.46B | $1.24B | $1.27B | $1.61B | $1.29B | $984.16M | $162.23M | $1.46B | $812.43M | $947.95M | $-271.80M | $1.47B | $1.76B | $629.54M | $608.25M | $800.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 1.06% | 1.22% | 0.20% | 0.80% | - | 1.23% | 1.08% | 1.05% | 1.00% | 1.09% | 0.97% | 1.11% | 1.29% | 1.18% | 1.04% | 1.11% |
5 analysts predict HUM's average Quarter EBITDA for Dec 23 to be $1.46B, with a high of $1.48B and a low of $1.45B. This is 4.18% upper than Humana's previous annual EBITDA (Sep 23) of $1.40B.
Humana Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 5 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $832.00M | $959.00M | $1.24B | $-13.00M | $1.20B | - | $930.00M | $-9.00M | $1.53B | $588.00M | $828.00M | $-280.00M | $1.34B | $1.83B | $473.00M | $512.00M | $689.00M |
| Avg Forecast | $285.25M | $728.67M | $1.00B | $1.07B | $60.24M | $579.11M | $852.97M | $926.22M | $-154.16M | $403.23M | $707.58M | $1.05B | $97.41M | $864.29M | $1.06B | $957.82M | $176.30M | $1.60B | $929.67M | $757.17M | $-12.90M | $1.46B | $585.43M | $756.46M | $-282.09M | $1.21B | $1.42B | $400.23M | $493.38M | $621.30M |
| High Forecast | $291.59M | $744.86M | $1.02B | $1.09B | $61.58M | $591.97M | $871.92M | $946.79M | $-151.31M | $444.24M | $723.30M | $1.26B | $118.28M | $908.96M | $1.08B | $1.15B | $180.21M | $1.92B | $929.67M | $908.60M | $-10.32M | $1.75B | $702.51M | $907.75M | $-225.67M | $1.45B | $1.70B | $480.28M | $592.06M | $745.56M |
| Low Forecast | $279.98M | $715.20M | $983.03M | $1.05B | $59.13M | $568.40M | $837.20M | $909.09M | $-157.58M | $377.03M | $694.50M | $842.88M | $-6.42M | $851.02M | $1.04B | $766.25M | $173.03M | $1.28B | $929.67M | $605.73M | $-15.49M | $1.17B | $468.34M | $605.17M | $-338.51M | $969.00M | $1.14B | $320.18M | $394.71M | $497.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.91% | 1.29% | -0.07% | 0.75% | - | 1.23% | 0.70% | 1.05% | 1.00% | 1.09% | 0.99% | 1.11% | 1.29% | 1.18% | 1.04% | 1.11% |
Humana's average Quarter net income forecast for Dec 23 is $97.41M, with a range of $-6.42M to $118.28M. HUM's average Quarter net income forecast represents a -88.29% decrease compared to the company's last Quarter net income of $832.00M (Sep 23).
Humana SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 5 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.40B | $2.60B | $2.12B | $2.01B | $3.07B | $2.51B | $2.35B | $2.12B | $2.13B | $1.89B |
| Avg Forecast | $3.79B | $3.79B | $3.91B | $3.94B | $3.57B | $3.58B | $3.69B | $3.75B | $3.53B | $3.53B | $3.51B | $3.51B | $3.14B | $3.15B | $3.18B | $3.26B | $2.77B | $2.73B | $2.89B | $2.34B | $3.13B | $2.48B | $2.11B | $1.83B | $3.16B | $2.27B | $1.83B | $1.79B | $2.05B | $1.70B |
| High Forecast | $3.86B | $3.85B | $3.97B | $4.00B | $3.63B | $3.64B | $3.75B | $3.81B | $3.59B | $3.56B | $3.57B | $3.57B | $3.19B | $3.30B | $3.24B | $3.31B | $2.82B | $3.27B | $2.89B | $2.41B | $3.76B | $2.97B | $2.53B | $2.20B | $3.79B | $2.73B | $2.19B | $2.15B | $2.46B | $2.04B |
| Low Forecast | $3.74B | $3.73B | $3.85B | $3.88B | $3.52B | $3.53B | $3.64B | $3.69B | $3.48B | $3.49B | $3.46B | $3.46B | $3.12B | $3.05B | $3.14B | $3.21B | $2.73B | $2.18B | $2.89B | $2.28B | $2.50B | $1.98B | $1.69B | $1.47B | $2.53B | $1.82B | $1.46B | $1.43B | $1.64B | $1.36B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.05% | 1.00% | 1.09% | 0.97% | 1.11% | 1.29% | 1.18% | 1.04% | 1.11% |
Humana's average Quarter SG&A projection for Mar 22 is $2.34B, based on 6 Wall Street analysts, with a range of $2.28B to $2.41B. The forecast indicates a -31.06% fall compared to HUM last annual SG&A of $3.40B (Dec 21).
Humana EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 5 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.74 | $7.70 | $9.91 | $-0.10 | $9.45 | - | $7.32 | $-0.07 | $11.91 | $4.57 | $6.42 | $-2.12 | $10.12 | $13.83 | $3.58 | $3.87 | $5.16 |
| Avg Forecast | $2.36 | $6.04 | $8.30 | $8.83 | $0.50 | $4.80 | $7.07 | $7.68 | $-1.28 | $3.34 | $5.86 | $6.12 | $0.81 | $7.16 | $8.76 | $9.27 | $1.46 | $6.28 | $7.67 | $6.80 | $1.16 | $4.68 | $6.83 | $7.07 | $-2.37 | $2.81 | $10.27 | $4.66 | $2.20 | $4.58 |
| High Forecast | $2.42 | $6.17 | $8.48 | $9.02 | $0.51 | $4.91 | $7.23 | $7.85 | $-1.25 | $3.68 | $5.99 | $6.25 | $0.98 | $7.53 | $8.95 | $9.48 | $1.49 | $6.42 | $7.67 | $7.07 | $1.20 | $4.86 | $7.09 | $7.35 | $-2.29 | $2.92 | $10.67 | $4.85 | $2.28 | $4.75 |
| Low Forecast | $2.32 | $5.93 | $8.15 | $8.66 | $0.49 | $4.71 | $6.94 | $7.53 | $-1.31 | $3.12 | $5.76 | $6.01 | $-0.05 | $7.05 | $8.60 | $9.10 | $1.43 | $6.16 | $7.67 | $6.59 | $1.12 | $4.53 | $6.61 | $6.85 | $-2.46 | $2.72 | $9.95 | $4.52 | $2.13 | $4.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.88% | 1.07% | -0.07% | 1.51% | - | 1.08% | -0.06% | 2.55% | 0.67% | 0.91% | 0.89% | 3.60% | 1.35% | 0.77% | 1.76% | 1.13% |
According to 5 Wall Street analysts, Humana's projected average Quarter EPS for Dec 23 is $0.81, with a low estimate of $-0.05 and a high estimate of $0.98. This represents a -88.02% decrease compared to HUM previous annual EPS of $6.74 (Sep 23).
Humana Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVS | CVS Health | $57.98 | $103.77 | 78.98% | Hold |
| HUM | Humana | $321.56 | $500.84 | 55.75% | Hold |
| CNC | Centene | $75.35 | $92.60 | 22.89% | Buy |
| ELV | Elevance Health | $550.84 | $556.91 | 1.10% | Buy |
| MOH | Molina Healthcare | $358.20 | $358.63 | 0.12% | Hold |
| UNH | UnitedHealth Group | $594.32 | $569.20 | -4.23% | Buy |
| CI | Cigna | $364.72 | $318.74 | -12.61% | Buy |
| ALHC | Alignment Healthcare | $11.89 | $9.50 | -20.10% | Buy |
HUM Forecast FAQ
Is Humana a good buy?
No, according to 21 Wall Street analysts, Humana (HUM) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 47.62% of HUM's total ratings.
What is HUM's price target?
Humana (HUM) average price target is $500.84 with a range of $360 to $652, implying a 55.75% from its last price of $321.56. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Humana stock go up soon?
According to Wall Street analysts' prediction for HUM stock, the company can go up by 55.75% (from the last price of $321.56 to the average price target of $500.84), up by 102.76% based on the highest stock price target, and up by 11.95% based on the lowest stock price target.
Can Humana stock reach $500?
HUM's average twelve months analyst stock price target of $500.84 supports the claim that Humana can reach $500 in the near future.
What is Humana's current price target trend?
1 Wall Street analyst forecast a $400 price target for Humana (HUM) this month, up 24.39% from its last price of $321.56. Compared to the last 3 and 12 months, the average price target increased by 22.03% and increased by 15.93%, respectively.
What are Humana's analysts' financial forecasts?
Humana's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.4B (high $120.42B, low $116.71B), average EBITDA is $6.78B (high $6.9B, low $6.69B), average net income is $2.42B (high $2.47B, low $2.37B), average SG&A $14.58B (high $14.83B, low $14.38B), and average EPS is $20.04 (high $20.49, low $19.67). HUM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $125.2B (high $127.34B, low $123.42B), average EBITDA is $7.17B (high $7.3B, low $7.07B), average net income is $3.08B (high $3.15B, low $3.02B), average SG&A $15.42B (high $15.69B, low $15.2B), and average EPS is $25.53 (high $26.1, low $25.06).
Did the HUM's actual financial results beat the analysts' financial forecasts?
Based on Humana's last annual report (Dec 2022), the company's revenue was $92.87B, beating the average analysts forecast of $92.28B by 0.64%. Apple's EBITDA was $4.81B, missing the average prediction of $5.82B by -17.31%. The company's net income was $2.81B, missing the average estimation of $3.47B by -19.06%. Apple's SG&A was $0, missing the average forecast of $10.72B by -100.00%. Lastly, the company's EPS was $21.8, missing the average prediction of $22.2 by -1.82%. In terms of the last quarterly report (Sep 2023), Humana's revenue was $26.42B, beating the average analysts' forecast of $25.57B by 3.33%. The company's EBITDA was $1.4B, missing the average prediction of $1.47B by -4.24%. Humana's net income was $832M, missing the average estimation of $864.29M by -3.74%. The company's SG&A was $0, missing the average forecast of $3.15B by -100.00%. Lastly, the company's EPS was $6.74, missing the average prediction of $7.16 by -5.90%